The Research Institute of Molecular Pathology is a biomedical research center, which conducts curiosity-driven basic research in the molecular life sciences. The IMP is located at the Vienna Biocenter in Vienna, Austria, the institute employs around 250 people from 36 nations, of which approximately 200 are scientists. The working language at the IMP is English, the IMP was established in 1985 and is funded by the pharmaceutical company Boehringer Ingelheim and research grants. Research at the IMP aims to elucidate mechanisms and principles that underlie complex biological processes, the research in these fields is pursued by 15 independent research groups, headed by principle investigators. Under the directorship of Max Birnstiel, the first institute building was opened in 1988, in 1992, three institutes of the faculties of science and medicine of the University of Vienna moved into a nearby building, todays Max F. Perutz Laboratories. This created the basis for referring to the area as the Vienna Biocenter, in 1993, Boehringer Ingelheim took over the IMP shares of Genentech. Following Max Birnstiels retirement in 1997, Kim Nasmyth became scientific director, in 2006, two institutes of the Austrian Academy of Sciences were opened in the vicinity of the IMP, the Institute of Molecular Biotechnology and the Gregor Mendel Institute. The three institutes cooperate closely by maintaining shared facilities, in the same year, Barry Dickson became the IMPs scientific director. Since 2013, Jan-Michael Peters is scientific director of the IMP, in late 2016, the IMP moved into its new building. Scientists at the IMP publish 60 to 90 papers in international peer-review journals per year,93 patents were filed based on discoveries made at the institute since 1985. IMP faculty was awarded 13 ERC Grants since the establishment of this grant scheme in 2007, four IMP faculty members received Wittgenstein Awards since 1996. Acceptance into the program is competitive and based on a selection procedure. There are two each year, deadlines are April 30 and November 15. Participation in the program is a condition for doing a PhD at the IMP, the current IMP building at Campus-Vienna-Biocenter 1 was opened in 2017. It comprises 15,000 square meters of floor space and 8,000 square meters of net area. The building contains 3,000 square meters for laboratories and 2,000 square meters for offices, the buildings has six seminar rooms and technical facilities. The project costs of 52 million Euros were born by the IMPs main sponsor Boehringer Ingelheim, the four research institutes of the Vienna Biocenter maintain a number of shared services jointly called VBC Core Facilities. The Scientific Advisory Board, consisting of distinguished scientists, meets once a year and discusses the quality, significance, the SAB is chaired by Leslie Vosshall of Rockefeller University
Image: Entrance area
Laboratory at the IMP. Up to three research groups share a lab to support communication and exchange.
Research Institute of Molecular Pathology (IMP), outside view.
Split-level architecture blending different floors and functions of the new IMP building.